Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00110500 · ClinicalTrials.gov registry record · Phase 1
Clinical Trial of SB-509-0401 in Subjects With Diabetic Neuropathy
A Phase 1 study, sponsored by Sangamo Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00110500 is a Phase 1 study that has completed, run by Sangamo Therapeutics. The registered enrollment target is 12 participants.
The verdict
NCT00110500, a Phase 1 study, has completed, sponsored by Sangamo Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the clinical and laboratory safety of SB-509 when given as a single treatment by an intramuscular injection to subjects with diabetic neuropathy.
Interventions
- GENETIC hVEGF-A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2005-04 |
| Est. Completion | 2008-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00110500
The ClinicalTrials.gov registry entry for NCT00110500 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sangamo Therapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which hVEGF-A is the first listed.
NCT00110500 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00110500 about?
NCT00110500 is a clinical study titled "Clinical Trial of SB-509-0401 in Subjects With Diabetic Neuropathy". The purpose of this study is to evaluate the clinical and laboratory safety of SB-509 when given as a single treatment by an intramuscular injection to subjects with diabetic neuropathy.
What is the current status of trial NCT00110500?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2005-04. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00110500?
The interventions under investigation include: hVEGF-A (GENETIC).
Who is sponsoring clinical trial NCT00110500?
This trial is sponsored by Sangamo Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.